- Home
- TVTX vs ACT Comparison
TVTX vs ACT Comparison
Compare TVTX & ACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVTX | ACT |
|---|---|---|
| Founded | N/A | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 6.0B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TVTX | ACT |
|---|---|---|
| Price | $56.64 | $45.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 4 |
| Target Price | $40.62 | ★ $44.25 |
| AVG Volume (30 Days) | ★ 1.8M | 263.7K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.90% |
| EPS Growth | ★ 92.89 | 3.43 |
| EPS | N/A | ★ 1.18 |
| Revenue | N/A | ★ $1,235,827,000.00 |
| Revenue This Year | $44.76 | $4.06 |
| Revenue Next Year | $35.51 | $2.33 |
| P/E Ratio | ★ N/A | $39.31 |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $15.03 | $33.94 |
| 52 Week High | $60.10 | $47.28 |
Technical Indicators
Market Signals| Indicator | TVTX | ACT |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 57.29 |
| Support Level | $54.87 | $39.78 |
| Resistance Level | $59.89 | $46.34 |
| Average True Range (ATR) | 2.39 | 1.04 |
| MACD | -0.64 | 0.01 |
| Stochastic Oscillator | 52.02 | 55.06 |
Price Performance
Historical ComparisonAbout TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.